TVTX - Travere inks licensing deal for sparsentan in Asia
2024-01-25 17:55:11 ET
More on Travere Therapeutics
- Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M
- Travere to seek FDA approval for Filspari in IgAN but not FSGS
- Travere Therapeutics, Inc. (TVTX) Q3 2023 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Travere Therapeutics
- Historical earnings data for Travere Therapeutics